| 2026-08-14 | Deck | Corporate Presentation |
| 2026-08-13 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-13 | Press release | Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results |
| 2026-08-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-13 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-05 | Press release | Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candid |
| 2026-08-05 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-04 | 8-K | Form 8-K, Item 5.02 |
| 2026-08-03 | Press release | Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday |
| 2026-07-29 | Press release | Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone |
| 2026-07-29 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-09 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-19 | Press release | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (mi |
| 2026-05-19 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-14 | Press release | Eton Pharmaceuticals Reports First Quarter 2026 Financial Results |
| 2026-05-14 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-14 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Press release | Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday |
| 2026-05-01 | Press release | Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy |
| 2026-05-01 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-27 | Press release | Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 |
| 2026-04-27 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-24 | Proxy | Definitive proxy statement |
| 2026-04-16 | Press release | Eton Pharmaceuticals Announces CFO Succession Plan |
| 2026-04-16 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-15 | 8-K | Form 8-K, Item 1.01 |
| 2026-03-19 | Press release | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-19 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-19 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-03 | Press release | Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday |
| 2026-03-02 | Press release | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® ( |
| 2026-03-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-02-25 | Press release | Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution |
| 2026-02-25 | 8-K | Form 8-K, Item 8.01 |
| 2026-02-20 | Press release | Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th |
| 2026-02-02 | Press release | Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate |
| 2026-02-02 | 8-K | Form 8-K, Item 8.01 |
| 2025-12-04 | 8-K | Form 8-K, Item 7.01 |
| 2025-11-18 | 8-K | Form 8-K/A, Item 2.01 |
| 2025-11-06 | Press release | Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results |